- Home | Harrow, Inc.
Harrow is redefining the standard of care in eyecare with a portfolio of trusted, high-value pharmaceutical solutions that deliver proven safety, efficacy, and affordability
- Harrow Announces First-Quarter 2025 Financial Results
Harrow, Inc (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market
- SEC Filings | Harrow, Inc.
The Investor Relations website contains information about Harrow, Inc 's business for stockholders, potential investors, and financial analysts
- Corporate Presentation November 2025 - harrow. com
Harrow was founded to advance the standard of eye care and deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes
- Careers | Harrow, Inc.
At Harrow, our values aren’t just guiding words—they shape how we grow, innovate, and work together Humility, ownership, preparedness, and entrepreneurship create the foundation for a culture where initiative is celebrated, creativity thrives, and impact is real
- Harrow Announces Agenda and Speakers for Investor Analyst Day
Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes
- 0001493152-25-012840 | 8-K | iXBRL Viewer | Harrow INC
Harrow INC SEC filing: Form 8-K iXBRL on 09 09 2025 (0001493152-25-012840)
- Compliance with California Health Safety Code - harrow. com
Eye, LLC (“Harrow”) has established a CCP in accordance with the OIG Guidance and has policies in place to foster compliance with the PhRMA Code For purposes of compliance with the requirements of the California Compliance Law and as part of the CPP, Harrow has established a specific annual aggregate dollar limit of $2,000 on gifts
|